PepGen Inc. (PEPG)
Nasdaq · Healthcare · Biotechnology
$2.36+3.51%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $163M
- 52-week range
- $1.31 – $7.80
- 52-week change
- −53.56%
- EPS (trailing)
- −$1.01
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Net income
- −$89.7M
- Diluted EPS
- −$2.12
- Free cash flow
- −$81.9M
From the company’s annual report on SEC EDGAR.
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Headquarters: Boston, United States · 57 employees · pepgen.com